IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
Title:
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
Author:
Stabile, L.P. Egloff, A.M. Gibson, M.K. Gooding, W.E. Ohr, J. Zhou, P. Rothenberger, N.J. Wang, L. Geiger, J.L. Flaherty, J.T. Grandis, J.R. Bauman, J.E.